Katarina Luptakova - 05 Sep 2023 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Medical Officer
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
05 Sep 2023
Net transactions value
$0
Form type
3
Filing time
07 Sep 2023, 16:23:28 UTC
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) 05 Sep 2023 Common Stock 44,210 $9.69 Direct F1
holding XLO Stock Option (right to buy) 05 Sep 2023 Common Stock 15,000 $2.37 Direct F2
holding XLO Stock Option (right to buy) 05 Sep 2023 Common Stock 35,000 $2.69 Direct F3
holding XLO Stock Option (right to buy) 05 Sep 2023 Common Stock 25,000 $2.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on December 7, 2021 for 44,210 shares. On December 2, 2022, 25% of the shares underlying the option vested and the remainder continues to vest in equal monthly installments thereafter through December 2, 2025.
F2 The option was granted on November 1, 2022 for 15,000 shares. The shares underlying the option began vesting on December 1, 2022 and shall vest in equal monthly installments thereafter through November 1, 2026.
F3 The option was granted on January 1, 2023 for 35,000 shares. The shares underlying the option began vesting on February 1, 2023 and shall vest in equal monthly installments thereafter through January 1, 2027.
F4 The option was granted on August 16, 2023 for 25,0000 shares and shall vest with respect to 1/3 of the shares underlying the option on August 16, 2024 and with respect to the remaining 2/3 of the shares underlying the option on August 16, 2025.

Remarks:

Exhibit Index: 24.1 Power of Attorney